Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dainippon Sumitomo Launches Parkinson’s Disease Drug Trerief In Japan

This article was originally published in PharmAsia News

Executive Summary

Osaka-based Dainippon Sumitomo Pharma launched March 13 Trerief (zonisamide), which was approved in Japan in January to treat movement disorders such as akinesia and muscle rigidity associated with Parkinson's disease. DSP estimates that there are 150,000 to 160,000 patients in Japan, and that sales for the first year will be around ¥1.1 billion, with a potential rise to ¥5.4 billion by 2017. Zonisamide was previously approved as an antiepileptic drug and sold under the name Excergran. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071072

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel